The drugmaker said the results for giredestrant open the door to adding a treatment option at an early stage of the cancer, ...

The second-line endocrine therapy landscape in hormone receptor (HR)-positive, HER2-negative advanced breast cancer is ...

Roche's experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast cancer ...

By embedding standardized questionnaires and algorithms into routine visits, providers can evaluate risk factors such as age, ...

Roche has reported another phase 3 win for its oral selective estrogen receptor degrader (SERD). Success at a planned interim ...

The rationale is really strong since we're often making decisions for our patients based on single features or ...

Topline data were announced from a phase 3 trial evaluating giredestrant for the adjuvant treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ...

A real-world analysis of more than 60,000 patients in the US finds median survival increased by almost 7 months from 2011 to ...

During a routine mammogram, doctors found something unusual in Patty Schone’s left breast. But the real danger was actually ...

Op-Ed: A human connection can be a meaningful part of healing and reclaiming your well-being after cancer.

The Post Surgery Everyday Bra, manufactured for brands by MAS Femography, combines medical insight and apparel innovation, ...

A new law is providing better access to breast cancer screenings for Oklahomans. 2 News’ Naomi Keitt listened to experts to ...